Navigation Links
ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
Date:2/20/2009

FREDERICK, Md., Feb. 20 /PRNewswire/ -- ImQuest Life Sciences presented important new results on the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the 16th Conference on Retroviruses and Opportunistic Infections held last week in Montreal. Presentations focused on the results of IND-directed development of the HIV therapeutic IQP-0410 and the efficacy and formulation of IQP-0528 as a topical microbicide to prevent the sexual transmission of HIV. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a novel dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety profile, and enhanced sensitivity against multi-drug resistant viruses isolated from patients. For prevention, the lead pyrimidinedione exhibits characteristics of an ideal microbicide, including the inhibition of two early steps in the viral replication pathway as well as its lack of toxicity to the cells and normal bacterial flora of the vaginal microenvironment.

Nick Kaludov, Ph.D. (Director, Product Development) and Todd B. Parsley, Ph.D. (Director, Molecular Virology) presented data on the IQP-0410 development programs which demonstrate the potential for oral, once per day dosing of IQP-0410. The highly attractive safety profile, ability of the compound to positively interact in combination with other HIV drugs, and the high intrinsic genetic barrier to resistance of the clinical candidate, was emphasized in these presentations. ImQuest, in collaboration with their drug development partner Samjin Pharmaceutical Co. Ltd of Seoul, Korea, have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance. It is believed that these compounds will prolong the therapeutic utility of the pyrimidinediones by preventing HIV from easily evading the action of the drug and will allow ImQuest to develop even more potent HI
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
4. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
5. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
6. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
9. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
10. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
11. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... LUVOX(R) CR Approved and Launched - Screening C...al, PALO ALTO, Calif., May 13 Jazz,Pharmaceutica...l results for,the quarter ended March 31, 2008., ...8 were $14.6 million,compared to $14.1 million for...m oxybate oral solution) net sales for the first q...
...upport for Grassley-Kohl Bill Newest Addition to L... Agenda, INDIANAPOLIS, May 13 Today Eli Lilly a...the newly revised Physicians,Payments Sunshine Act...sley,(R-Iowa) and Herbert Kohl (D-Wisconsin). The ...y of payments to physicians by medical device,medi...
...AKE FOREST, Ill., May 13 Hospira, Inc.,(NYSE: HS...ion delivery,company, announced today that Barbara... board of directors. Bowles brings strong investme...p positions held at major,multinational consumer g...s. The addition of Bowles expands Hospira,s board ...
Other Biology Technology:Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 6Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 7Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 8Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians 2Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians 3Hospira Expands Board of Directors 2
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2CCNY professor foresees rising Antarctic snowmelt 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 1Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 3Senior Citizens Bureau Creates New Resourceful Divisions 48034 1Senior Citizens Bureau Creates New Resourceful Divisions 48034 2Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference 48033 1
...earch suggests that lowering cholesterol may block...t by Solomon et al, "Ezetimibe Is an Inhibitor of ...ue of The American Journal of Pathology . , High... heart disease, but may also contribute to cancer ...st common non-skin cancer in the United States, af...
... the human genome eight years ago, enormous progre.... Nevertheless, the function of most human genes i... in determining the function of a gene or protein ...undreds of other organisms that are experimentally...ted genes or proteins identified in these database...
...3, 2009 The legacy of nuclear weapons and nuclear...ment at dozens of sites across the United States a...anium. The uranium is transported through ground w...gy, uranium immobilization in contaminated ground ... of organic molecules known as electron donors to ...
Other Biology News:Lowering your cholesterol may decrease your risk of cancer 2Relationships in rank and file 2Relationships in rank and file 3Relationships in rank and file 4Patience pays off with methanol for uranium bioremediation 2
ImageQuant 300 from GE Healthcare, formerly Amersham Biosciences
Feline IL-12 / IL-23 p40, Unconjugated from R&D Systems
Rabbit Anti-ISOCITRATE DEHYDROGENASE Polyclonal Antibody, Unconjugated from AbD Serotec
... two highly efficient methods of identifying recom...consuming plasmid preparation. By using the large-...s to transfer partial colonies of E. coli bacteria...solutions provided by the kits and immediately run...
Biology Products: